Matthew S. Parsons
University of Rochester
MoleInternal medicineOncologyDermatologyPediatricsOptic neuritisMonoclonal antibody therapyCD19AlemtuzumabMEDLINEAutoimmunityTrigeminal neuralgiaMultiple sclerosisRituximabNatalizumabCase conferenceNeurology clinicFacial painClinical courseMonoclonal antibodyMedicineImmune system
Publications 3
#2Nick Hogan (University of Texas at Austin)H-Index: 1
Last. Teresa C. FrohmanH-Index: 37
view all 18 authors...
The patient is a right-handed White woman with relapsing-remitting MS diagnosed subsequent to left acute optic neuritis (AON). She described a previous transient episode of severe, electrical, and paroxysmal facial pain consistent with trigeminal neuralgia. Initial MRI demonstrated supratentorial
#1Nidhiben Anadani (UR: University of Rochester)
#2Megan HylandH-Index: 5
Last. Teresa Frohman (UR: University of Rochester)H-Index: 1
view all 16 authors...
A 38-year-old woman with MS receiving natalizumab presented to the neurology clinic with the complaint of a new neurologic symptom. ### Clinical course The patient had a 6-year history of clinically stable MS, albeit exhibiting radiographic progression despite strict adherence to daily
Objective To determine whether the punctuated administration of low-dose rituximab, temporally linked to B-cell hyperrepopulation (defined when the return of CD19+ B cells approximates 40%–50% of baseline levels as measured before alemtuzumab treatment inception), can mitigate alemtuzumab-associated secondary autoimmunity. Methods In this hypothesis-driven pilot study, 10 patients received low-dose rituximab (50–150 mg/m2), a chimeric anti-CD20 monoclonal antibody, after either their first or se...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.